Vascular complications are a leading cause of mortality and morbidity in diabetic individuals. Despite recent advances using pharmacotherapy, a cure for diabetic microvascular complications (MVC) has yet to be realized. A conceptual and technical breakthrough is imperative to identify novel targets, and a strategy to cure these complications is paramount. We believe that our provocative preliminary data coupled with recent evidence of a potential role of endothelial progenitor cells (EPCs) in vascular repair and the discovery of the vasoprotective axis of the renin-angiotensin-system (RAS) offer such a breakthrough. The protective axis of the RAS involves the angiotensin converting enzyme 2 (ACE2) which is present in both endothelial cells and EPCs and generates angiotensin-(1-7) which acting through the Mas, attenuates the vasoconstrictive, proliferative, fibrotic and hypertrophic effects of angiotensin II, the key member of the deleterious axis of RAS. In this proposal we utilize retinopathy as the MVC to test our hypothesis that the ACE/ACE2 balance within EPCs dictates their reparative capability and can therefore predict progression of retinal MVC. If MVC are already present, then genetically modifying EPCs utilizing AAV technology to increase endogenous levels of ACE2 will enhance their reparative function and reverse MVC. We put forth the following Specific Aims to test our hypothesis:
Aim 1 : Investigate whether the ACE/ACE2 imbalance within EPCs will predict progression of MVC.
Aim 2 : Test the hypothesis if the absence of ACE2 in the systemic vasculature will accelerate progression while overexpression will prevent development and progression retinovascular complications.
Aim 3 : Investigate the hypothesis that increased ACE2/Ang-(1-7) expression within the retina will stimulate mobilization, homing and reparative potential of EPCs. This integrative and multidimensional proposal is extremely innovative both conceptually and technically because it will: (i) provide evidence for our hypothesis;(ii) establish the mechanism by which the activation of the ACE2/Ang-(1-7)-Mas receptor axis within EPCs sustains cellular reparative function in diabetes;(iii) determine whether the state of the RAS in EPCs can predict the progression of retinopathy;(iv) use the highly innovative VESsel GENeration (VESGEN) technology to delineate vascular remodeling in the retina and (iv) put us in an outstanding position to transition into the clinical arena using cells that have their protective RAS axis activated, either genetically or pharmacologically, for treatment of diabetic retinopathy

Public Health Relevance

The focus of our proposal is to investigate if the balance of vasoprotective axis vs. vasodeleterious axis of the RAS within EPCs can predict progression of MVC in diabetes. Furthermore we will study if correction of this imbalance in the EPCs of diabetic patients would prevent the progression/attenuation of MVC. Outcome of these experiments will be a significant advancement in the use of ACE/ACE2 ratio as a predictor of diabetic patients and development of novel stem cell-based therapy to prevent MVC, single most important cause of diabetes-linked mortality and morbidity.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01HL110170-04
Application #
8725220
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Reid, Diane M
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Beli, Eleni; Dominguez 2nd, James M; Hu, Ping et al. (2016) CX3CR1 deficiency accelerates the development of retinopathy in a rodent model of type 1 diabetes. J Mol Med (Berl) 94:1255-1265
Wert, Katherine J; Mahajan, Vinit B; Zhang, Lijuan et al. (2016) Neuroretinal hypoxic signaling in a new preclinical murine model for proliferative diabetic retinopathy. Signal Transduct Target Ther 1:
Bhatwadekar, Ashay D; Duan, Yaqian; Chakravarthy, Harshini et al. (2016) Ataxia Telangiectasia Mutated Dysregulation Results in Diabetic Retinopathy. Stem Cells 34:405-17
Dominguez 2nd, James M; Hu, Ping; Caballero, Sergio et al. (2016) Adeno-Associated Virus Overexpression of Angiotensin-Converting Enzyme-2 Reverses Diabetic Retinopathy in Type 1 Diabetes in Mice. Am J Pathol 186:1688-700
Patel, Vaibhav B; Zhong, Jiu-Chang; Grant, Maria B et al. (2016) Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. Circ Res 118:1313-26
Patel, Vaibhav B; Takawale, Abhijit; Ramprasath, Tharmarajan et al. (2015) Antagonism of angiotensin 1-7 prevents the therapeutic effects of recombinant human ACE2. J Mol Med (Berl) 93:1003-13
Bhatwadekar, Ashay D; Yan, Yuanqing; Stepps, Valerie et al. (2015) miR-92a Corrects CD34+ Cell Dysfunction in Diabetes by Modulating Core Circadian Genes Involved in Progenitor Differentiation. Diabetes 64:4226-37
Dominguez 2nd, James M; Yorek, Mark A; Grant, Maria B (2015) Combination therapies prevent the neuropathic, proinflammatory characteristics of bone marrow in streptozotocin-induced diabetic rats. Diabetes 64:643-53
Sulaiman, Rania S; Quigley, Judith; Qi, Xiaoping et al. (2015) A Simple Optical Coherence Tomography Quantification Method for Choroidal Neovascularization. J Ocul Pharmacol Ther 31:447-54
Balaiya, S; Chalam, K V (2014) An In vitro Assay to Quantify Nitrosative Component of Oxidative Stress. J Mol Genet Med 8:

Showing the most recent 10 out of 27 publications